Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.

Frontiers in immunology - 1 Jan 2021

Zeng Jiayi, Li Xiangxue, Sander Max, Zhang Haipeng, Yan Guangmei, Lin Yuan

Abstract excerpt

The prognosis of malignant gliomas remains poor, with median survival fewer than 20 months and a 5-year survival rate merely 5%. Their primary location in the central nervous system (CNS) and its immunosuppressive environment with little T cell infiltration has rendered cancer therapies mostly ineffective, and breakthrough therapies such as immune checkpoint inhibitors (ICIs) have shown limited benefit. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Combined Modality Therapy
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Engineering

Share to Genetic Therapy

Share to Immunotherapy

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Source

Open in PubMed Open full text

Identifiers

PMID: 34675919
DOI: 10.3389/fimmu.2021.721830
PMCID: PMC8524046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.PMID 34675919Read ↗

Oncolytic Virotherapy in Glioma TumorsSemantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomasSemantic proximity Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

Gene Therapy for High Grade Glioma: The Clinical ExperienceSemantic proximity Read ↗

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screeningSemantic proximity Read ↗

Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)Semantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

Strategies in Gene Therapy for GlioblastomaSemantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

Oncolytic Virus Therapy for Glioblastoma MultiformeSemantic proximity Read ↗

Oncolytic Virotherapy: From Bench to BedsideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.